These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

256 related articles for article (PubMed ID: 12562140)

  • 1. Clinical experience with substance P receptor (NK1) antagonists in depression.
    Ranga K; Krishnan R
    J Clin Psychiatry; 2002; 63 Suppl 11():25-9. PubMed ID: 12562140
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Addition of an NK1 receptor antagonist to an SSRI did not enhance the antidepressant effects of SSRI monotherapy: results from a randomized clinical trial in patients with major depressive disorder.
    Ball WA; Snavely DB; Hargreaves RJ; Szegedi A; Lines C; Reines SA
    Hum Psychopharmacol; 2014 Nov; 29(6):568-77. PubMed ID: 25330122
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Substance-P antagonists: a new treatment for depression?
    Nutt D
    Lancet; 1998 Nov; 352(9141):1644-6. PubMed ID: 9853433
    [No Abstract]   [Full Text] [Related]  

  • 4. Lack of efficacy of the substance p (neurokinin1 receptor) antagonist aprepitant in the treatment of major depressive disorder.
    Keller M; Montgomery S; Ball W; Morrison M; Snavely D; Liu G; Hargreaves R; Hietala J; Lines C; Beebe K; Reines S
    Biol Psychiatry; 2006 Feb; 59(3):216-23. PubMed ID: 16248986
    [TBL] [Abstract][Full Text] [Related]  

  • 5. S41744, a dual neurokinin (NK)1 receptor antagonist and serotonin (5-HT) reuptake inhibitor with potential antidepressant properties: a comparison to aprepitant (MK869) and paroxetine.
    Millan MJ; Dekeyne A; Gobert A; Mannoury la Cour C; Brocco M; Rivet JM; Di Cara B; Lejeune F; Cremers TI; Flik G; de Jong TR; Olivier B; de Nanteuil G
    Eur Neuropsychopharmacol; 2010 Sep; 20(9):599-621. PubMed ID: 20483567
    [TBL] [Abstract][Full Text] [Related]  

  • 6. NK1 receptor antagonists for depression: Why a validated concept was abandoned.
    Rupniak NMJ; Kramer MS
    J Affect Disord; 2017 Dec; 223():121-125. PubMed ID: 28753469
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Elucidating the antidepressant actions of substance P (NK1 receptor) antagonists.
    Rupniak NM
    Curr Opin Investig Drugs; 2002 Feb; 3(2):257-61. PubMed ID: 12020057
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Can the placebo be the cure?
    Enserink M
    Science; 1999 Apr; 284(5412):238-40. PubMed ID: 10232967
    [No Abstract]   [Full Text] [Related]  

  • 9. Antidepressant-like activity of selective serotonin reuptake inhibitors combined with a NK1 receptor antagonist in the mouse forced swimming test.
    Chenu F; Guiard BP; Bourin M; Gardier AM
    Behav Brain Res; 2006 Sep; 172(2):256-63. PubMed ID: 16806519
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification, biological characterization and pharmacophoric analysis of a new potent and selective NK1 receptor antagonist clinical candidate.
    Di Fabio R; Alvaro G; Braggio S; Carletti R; Gerrard PA; Griffante C; Marchioro C; Pozzan A; Melotto S; Poffe A; Piccoli L; Ratti E; Tranquillini E; Trower M; Spada S; Corsi M
    Bioorg Med Chem; 2013 Nov; 21(21):6264-73. PubMed ID: 24075145
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Substance P receptor antagonists--a new antidepressive and anxiolytic mechanism?].
    Lieb K; Fiebich BL; Berger M
    Nervenarzt; 2000 Sep; 71(9):758-61. PubMed ID: 11042872
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Distinct mechanism for antidepressant activity by blockade of central substance P receptors.
    Kramer MS; Cutler N; Feighner J; Shrivastava R; Carman J; Sramek JJ; Reines SA; Liu G; Snavely D; Wyatt-Knowles E; Hale JJ; Mills SG; MacCoss M; Swain CJ; Harrison T; Hill RG; Hefti F; Scolnick EM; Cascieri MA; Chicchi GG; Sadowski S; Williams AR; Hewson L; Smith D; Carlson EJ; Hargreaves RJ; Rupniak NM
    Science; 1998 Sep; 281(5383):1640-5. PubMed ID: 9733503
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Imaging substance P receptors (NK1) in the living human brain using positron emission tomography.
    Hargreaves R
    J Clin Psychiatry; 2002; 63 Suppl 11():18-24. PubMed ID: 12562139
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antidepressant properties of substance P antagonists: relationship to monoaminergic mechanisms?
    Adell A
    Curr Drug Targets CNS Neurol Disord; 2004 Apr; 3(2):113-21. PubMed ID: 15078186
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of the NK1 antagonist, aprepitant, on response to oral and intranasal oxycodone in prescription opioid abusers.
    Walsh SL; Heilig M; Nuzzo PA; Henderson P; Lofwall MR
    Addict Biol; 2013 Mar; 18(2):332-43. PubMed ID: 22260216
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Neurokinin 1 receptor antagonists--between hope and disappointment].
    Rost K; Fleischer F; Nieber K
    Med Monatsschr Pharm; 2006 Jun; 29(6):200-5. PubMed ID: 16792196
    [TBL] [Abstract][Full Text] [Related]  

  • 17. NK1 receptor antagonism lowers occupancy requirement for antidepressant-like effects of SSRIs in the gerbil forced swim test.
    Lelas S; Li YW; Wallace-Boone TL; Taber MT; Newton AE; Pieschl RL; Davis CD; Molski TF; Newberry KS; Parker MF; Gillman KW; Bronson JJ; Macor JE; Lodge NJ
    Neuropharmacology; 2013 Oct; 73():232-40. PubMed ID: 23770339
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reward for persistence in substance P research.
    Wahlestedt C
    Science; 1998 Sep; 281(5383):1624-5. PubMed ID: 9767028
    [No Abstract]   [Full Text] [Related]  

  • 19. The neurokinin-1 receptor antagonist aprepitant in co-morbid alcohol dependence and posttraumatic stress disorder: a human experimental study.
    Kwako LE; George DT; Schwandt ML; Spagnolo PA; Momenan R; Hommer DW; Diamond CA; Sinha R; Shaham Y; Heilig M
    Psychopharmacology (Berl); 2015 Jan; 232(1):295-304. PubMed ID: 25030801
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Spotlight on paroxetine in psychiatric disorders in adults.
    Wagstaff AJ; Cheer SM; Matheson AJ; Ormrod D; Goa KL
    CNS Drugs; 2002; 16(6):425-34. PubMed ID: 12027788
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.